Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB1 | P20618 | 5/20 | 0.51 |
| ▸ | PSMB5 | P28074 | 5/20 | 0.51 |
| ▸ | PSMB2 | P49721 | 4/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.51 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.50 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.49 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | JAK1 | P23458 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21296752 | 0.92 | MCHR1 (0.50) | PSMB1PSMB5PSMB2LTA4HMCHR1 | |
| SCHEMBL21296751 | 0.91 | PSMB1 (0.50) | PSMB1PSMB5PSMB2LTA4HMCHR1 | |
| SCHEMBL21296746 | 0.91 | MCHR1 (0.49) | PSMB1PSMB5PSMB2LTA4HMCHR1 | |
| SCHEMBL21296836 | 0.89 | PSMB1 (0.51) | PSMB1PSMB5PSMB2LTA4HMCHR1 | |
| SCHEMBL21296743 | 0.88 | PSMB1 (0.48) | PSMB1PSMB5PSMB2LTA4HMCHR1 | |
| SCHEMBL21296797 | 0.87 | PSMB1 (0.52) | PSMB1PSMB5PSMB2LTA4HMCHR1 | |
| SCHEMBL21296812 | 0.87 | PSMB1 (0.52) | PSMB1PSMB5PSMB2LTA4HMCHR1 | |
| SCHEMBL21296755 | 0.86 | LTA4H (0.47) | PSMB1PSMB5PSMB2LTA4HMCHR1 | |
| SCHEMBL21296742 | 0.86 | PSMB1 (0.48) | PSMB1PSMB5PSMB2LTA4HMCHR1 | |
| SCHEMBL21296738 | 0.85 | MCHR1 (0.49) | PSMB1PSMB5PSMB2LTA4HMCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246943-A1 | MULTIFACETED APPROACH TO NOVEL INTERLEUKIN-6 INHIBITORS | University of Florida Research Fooundation, Incorporated (US) | 2024-07-25 | — | — | US | disclosed |
| US-11530181-B2 | IL-6 inhibitors and methods of treatment | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2022-12-20 | — | — | US | disclosed |
| US-11530181-B2 | IL-6 inhibitors and methods of treatment | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2022-12-20 | — | — | US | disclosed |
| WO-2022226133-A1 | MULTIFACETED APPROACH TO NOVEL INTERLEUKIN-6 INHIBITORS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2022-10-27 | — | — | WO | disclosed |
| US-20210206718-A1 | IL-6 INHIBITORS AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2021-07-08 | — | — | US | disclosed |
| US-20210206718-A1 | IL-6 INHIBITORS AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2021-07-08 | — | — | US | disclosed |
| WO-2019165158-A1 | IL-6 INHIBITORS AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2019-08-29 | — | — | WO | disclosed |
| WO-2019165158-A1 | IL-6 INHIBITORS AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2019-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11530181-B2 | IL-6 inhibitors and methods of treatment | IL6, IL6ST, IL2 | PSMB1 4575/4885PSMB5 3962/4885PSMB2 4415/4885 |
| US-20240246943-A1 | MULTIFACETED APPROACH TO NOVEL INTERLEUKIN-6 INHIBITORS | IL6, IL6ST, IL36G | PSMB1 3699/4885PSMB5 3347/4885PSMB2 3041/4885 |
| US-20210206718-A1 | IL-6 INHIBITORS AND METHODS OF TREATMENT | IL6, IL6ST, IL2 | PSMB1 4575/4885PSMB5 3962/4885PSMB2 4415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.